Reslizumab

Covers intravenous reslizumab (Cinqair) 3 mg/kg IV every 4 weeks as add‑on maintenance therapy for adults (≥18 years) with severe eosinophilic asthma. Coverage requires documented uncontrolled asthma despite background therapy (eg, medium‑to‑high dose ICS/LABA), blood eosinophils ≥400 cells/μL measured within 3–4 weeks, history of exacerbations (≥2 systemic steroid bursts or ≥1 hospitalization/ICU in prior 12 months) and other specified clinical criteria; not covered for patients <18, for non‑FDA or unsupported off‑label uses, and is subject to the member’s benefit plan and applicable state rules.

"Drug therapy that is proven effective for the relevant diagnosis as supported by at least one authoritative source (e."

Sign up to see full coverage criteria, indications, and limitations.